GlassScriptPhysician profile
Christopher Verica
NPI 1386736627
$4,560.01
in general payments reported to CMS, 2019-2025
15 companies · $687 in 2025
The $687 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $877 · 2023: $1,704 · 2024: $1,048 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $80.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.18 |
| Education | $80.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,194.68 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,116.26 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $909.86 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $263.42 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $223.34 | 2022-2025 | Fanapt |
| Alkermes, INC. | $211.97 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.50 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $164.13 | 2022-2024 | Ingrezza |
| Corium, LLC | $125.28 | 2022-2023 | Azstarys |
| Neos Therapeutics, LP | $33.89 | 2022 | |
| Lundbeck LLC | $32.22 | 2021-2023 | Rexulti |
| Indivior INC. | $28.82 | 2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $20.92 | 2021 | |
| Axsome Therapeutics, INC. | $15.73 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Verica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.